Joshua Adkins and Jamie Lo will lead PMedIC, Pacific Northwest National Laboratory and Oregon Health & Science University’s joint research institute.
New research from PNNL and Washington State University collaborators connects the microbiome in the gut to circadian rhythms, suggesting a role for the microbiome as an internal regulator.
Katalenich was selected to attend the Grainger Foundation Frontiers of Engineering 2023 Symposium—an honor given to only 100 early-career engineers annually.
PNNL’s ARENA test bed analyzes how electrical cables degrade in extreme environments and how nondestructive examination inspection technologies can detect and locate damage.
The ChemSpace Tool, when fully developed, is intended to divide chemical space into three subsets: the detectable space, the identifiable space, and the region that includes compounds that are not detectable or identifiable.
As the world races to discover solutions for reaching net zero carbon emissions, a PNNL analysis quantifies the economic value of the existing nuclear power fleet and its carbon-free energy contributions.
SAGE is a high-efficiency genome integration strategy for bacteria that makes the stable introduction of new traits simple for newly discovered microbes.
Variations in burn severity are a key control on the chemical constituents of dissolved organic matter delivered to streams within a single burn perimeter.
Bobbie-Jo Webb-Robertson is a leader with a PhD in decision sciences & engineering systems from Rensselaer Polytechnic Institute and experience in managing complex scientific programs and line organizations. She assumed the role 3/13/23.
A new nano-optical bioimaging technology in development at PNNL enables researchers to watch climate-bellwether microbes exchange metabolites and other essential signals.
A multi-omics analysis provides the framework for gaining insights into the structure and function of microbial communities across multiple habitats on a planetary scale
Gosline works to develop computational algorithms that are uniquely targeted for rare disease work by doing foundational research in model system development. This work can be expanded to all model systems in human disease.
Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.